AU2009287340B2 - Prevention, treatment and diagnosis of P.gingivalis infection - Google Patents

Prevention, treatment and diagnosis of P.gingivalis infection Download PDF

Info

Publication number
AU2009287340B2
AU2009287340B2 AU2009287340A AU2009287340A AU2009287340B2 AU 2009287340 B2 AU2009287340 B2 AU 2009287340B2 AU 2009287340 A AU2009287340 A AU 2009287340A AU 2009287340 A AU2009287340 A AU 2009287340A AU 2009287340 B2 AU2009287340 B2 AU 2009287340B2
Authority
AU
Australia
Prior art keywords
seq
sequence
gingivalis
peptide
chimeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2009287340A
Other languages
English (en)
Other versions
AU2009287340A1 (en
Inventor
Neil Martin O'brien Simpson
Eric Charles Reynolds
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oral Health Australia Pty Ltd
Original Assignee
Oral Health Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2008904476A external-priority patent/AU2008904476A0/en
Application filed by Oral Health Australia Pty Ltd filed Critical Oral Health Australia Pty Ltd
Priority to AU2009287340A priority Critical patent/AU2009287340B2/en
Publication of AU2009287340A1 publication Critical patent/AU2009287340A1/en
Priority to AU2013203249A priority patent/AU2013203249A1/en
Application granted granted Critical
Publication of AU2009287340B2 publication Critical patent/AU2009287340B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0216—Bacteriodetes, e.g. Bacteroides, Ornithobacter, Porphyromonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1257—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Bacteridaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56955—Bacteria involved in periodontal diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21004—Trypsin (3.4.21.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/05—Hydrolases acting on acid anhydrides (3.6) acting on GTP; involved in cellular and subcellular movement (3.6.5)
    • C12Y306/05002—Small monomeric GTPase (3.6.5.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
AU2009287340A 2008-08-29 2009-08-28 Prevention, treatment and diagnosis of P.gingivalis infection Active AU2009287340B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2009287340A AU2009287340B2 (en) 2008-08-29 2009-08-28 Prevention, treatment and diagnosis of P.gingivalis infection
AU2013203249A AU2013203249A1 (en) 2008-08-29 2013-04-04 Prevention, treatment and diagnosis of P.gingivalis infection

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
AU2008904476 2008-08-29
AU2008904476A AU2008904476A0 (en) 2008-08-29 Prevention, treatment and diagnosis of P.gingivalis infection
AU2008905483A AU2008905483A0 (en) 2008-10-23 Prevention, treatment and diagnosis of P.gingivalis infection
AU2008905483 2008-10-23
US15113209P 2009-02-09 2009-02-09
US61/151,132 2009-02-09
AU2009903052A AU2009903052A0 (en) 2009-06-30 Prevention, treatment and diagnosis of P.gingivalis infection
AU2009903052 2009-06-30
AU2009287340A AU2009287340B2 (en) 2008-08-29 2009-08-28 Prevention, treatment and diagnosis of P.gingivalis infection
PCT/AU2009/001112 WO2010022463A1 (en) 2008-08-29 2009-08-28 Prevention, treatment and diagnosis of p.gingivalis infection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2013203249A Division AU2013203249A1 (en) 2008-08-29 2013-04-04 Prevention, treatment and diagnosis of P.gingivalis infection

Publications (2)

Publication Number Publication Date
AU2009287340A1 AU2009287340A1 (en) 2010-03-04
AU2009287340B2 true AU2009287340B2 (en) 2015-03-19

Family

ID=41720713

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009287340A Active AU2009287340B2 (en) 2008-08-29 2009-08-28 Prevention, treatment and diagnosis of P.gingivalis infection

Country Status (19)

Country Link
US (6) US8871213B2 (OSRAM)
EP (2) EP3255057B1 (OSRAM)
JP (2) JP2012500633A (OSRAM)
KR (1) KR101721904B1 (OSRAM)
CN (2) CN102203121A (OSRAM)
AU (1) AU2009287340B2 (OSRAM)
BR (1) BRPI0917321A2 (OSRAM)
CA (1) CA2735171C (OSRAM)
DK (1) DK2328914T3 (OSRAM)
ES (1) ES2633738T3 (OSRAM)
IL (1) IL211394B (OSRAM)
MX (1) MX2011001949A (OSRAM)
MY (1) MY178905A (OSRAM)
NZ (2) NZ591612A (OSRAM)
PL (1) PL2328914T3 (OSRAM)
RU (1) RU2535898C2 (OSRAM)
TW (1) TWI473626B (OSRAM)
WO (1) WO2010022463A1 (OSRAM)
ZA (1) ZA201101814B (OSRAM)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO652897A0 (en) 1997-04-30 1997-05-29 University Of Melbourne, The Synthetic peptide constructs for the diagnosis and treatment of periodontitis
US8129500B2 (en) 1997-12-10 2012-03-06 Csl Limited Porphyromonas gingivalis polypeptides and nucleotides
JP2009544279A (ja) 2006-06-27 2009-12-17 オーラル ヘルス オーストラリア ピーティーワイ リミテッド 歯周病の予防に有用なポルフィロモナス・ジンジバリスポリペプチド
ES2432690T3 (es) 2007-07-12 2013-12-04 Oral Health Australia Pty Ltd Tratamiento de biopelícula
WO2010022463A1 (en) * 2008-08-29 2010-03-04 Oral Health Australia Pty Ltd Prevention, treatment and diagnosis of p.gingivalis infection
US8140041B2 (en) * 2009-08-27 2012-03-20 Mediatek Inc. Tunable capacitive device with linearization technique employed therein
JP6310631B2 (ja) * 2011-10-18 2018-04-11 サンスター株式会社 歯周病原菌血漿または血清抗体価検査キット
US20170247674A1 (en) * 2014-10-14 2017-08-31 The Forsyth Institute Conjugates for delivery to mitochondria
CN110272472B (zh) * 2019-07-18 2020-09-15 河南科技大学 一种抗牙龈卟啉单胞菌及具核酸杆菌多肽及应用
CN111172177B (zh) * 2019-07-30 2023-08-08 镇江市江澜绿洲生物技术有限公司 cra4S1基因及其编码的蛋白和应用
RU2714506C1 (ru) * 2019-10-03 2020-02-18 федеральное государственное бюджетное образовательное учреждение высшего образования "Приволжский исследовательский медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО "ПИМУ" Минздрава России) Способ оценки эффективности лечения хронического катарального гингивита у детей
EP4255385A4 (en) * 2021-01-11 2025-03-26 Keystone Bio, Inc. ANTIGEN COMPOSITION(S) AND METHOD(S) AGAINST PORPHYROMONAS GINGIVALIS FOR THE PREVENTION AND/OR TREATMENT OF INFECTIONS AND/OR DISEASES
WO2023288204A1 (en) * 2021-07-13 2023-01-19 Keystone Bio, Inc. Diagnostics for porphyromonas gingivalis
CN116474096A (zh) * 2022-01-14 2023-07-25 中山大学附属口腔医院 靶向牙龈卟啉单胞菌RgpB在结直肠癌的治疗及预防中的应用
AU2023208227A1 (en) * 2022-01-20 2024-08-01 Denteric Pty Ltd Chimeric polypeptides
JP2025503079A (ja) * 2022-01-20 2025-01-30 デントリック ピーティーワイ エルティーディー キメラポリペプチド
WO2023137521A1 (en) * 2022-01-20 2023-07-27 Denteric Pty Ltd Chimeric polypeptides
WO2025017202A2 (en) * 2023-07-19 2025-01-23 Sanofi Porphyromonas gingivalis antigenic constructs
WO2025019902A1 (en) * 2023-07-26 2025-01-30 Denteric Pty Ltd Methods of treatment
WO2025019901A1 (en) * 2023-07-26 2025-01-30 Denteric Pty Ltd Rna vaccines
WO2025019900A1 (en) * 2023-07-26 2025-01-30 Denteric Pty Ltd Chimeric protein vaccine
WO2025019903A1 (en) * 2023-07-26 2025-01-30 Denteric Pty Ltd Rna vaccines for use in animal health
CN120157758B (zh) * 2025-03-26 2025-12-05 河南大学 牙龈卟啉单胞菌FimA单克隆抗体及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040005276A1 (en) * 1997-04-30 2004-01-08 Reynolds Eric Charles Synthetic peptide constructs for the diagnosis and treatment of periodontitis associated with porphyromonas gingivalis
WO2005019249A2 (en) * 2003-08-15 2005-03-03 University Of Florida Identification of porphyromonas gingivalis virulence polynucleotides for diagnosis, treatment, and monitoring of periodontal diseases

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837151A (en) 1980-05-19 1989-06-06 The Board Of Trustees Of The Leland Stanford Junior University, Stanford University Live vaccines comprising two mutations and foreign antigen
US5210035A (en) 1980-05-19 1993-05-11 Board Of Trustees Of Leland Stanford Jr. University Non-reventing live vaccines
US4735801A (en) 1982-09-07 1988-04-05 Board Of Trustees Of Leland Stanford Jr. University Novel non-reverting salmonella live vaccines
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5830710A (en) 1988-09-08 1998-11-03 University Of Florida Cloned porphyromonas gingivalis genes and probes for the detection of periodontal disease
WO1995000110A1 (en) 1993-06-28 1995-01-05 Lion Corporation Composition for oral cavity
US5523390A (en) 1993-09-10 1996-06-04 University Of Georgia Research Foundation, Inc. Porphyromonas gingivalis arginine-specific proteinase
EP0717747B1 (en) 1993-09-10 2003-06-04 The University Of Georgia Research Foundation, Inc. Porphyromonas gingivalis arginine-specific proteinase coding sequences
US5475097A (en) 1993-10-21 1995-12-12 University Of Georgia Research Foundation, Inc. Lysine-specific Porphyromonas gingivalis proteinase
US6017532A (en) 1993-09-10 2000-01-25 University Of Georgia Research Foundation, Inc. Porphyromonas gingivalis arginine-specific proteinase
JPH0797395A (ja) * 1993-09-28 1995-04-11 Kyowa Medex Co Ltd ポルフイロモナス・ジンジバリス線毛蛋白質の配列を含有するペプチド類及びその用途
EP0753577B1 (en) 1994-03-29 2002-07-24 Kyowa Hakko Kogyo Co., Ltd. Cell-surface polypeptide gene
AUPN627595A0 (en) * 1995-10-30 1995-11-23 University Of Melbourne, The Diagnostics and treatments of periodontal disease
US6129917A (en) 1996-03-22 2000-10-10 The University Of Georgia Research Foundation, Inc. Immunogenic compositions comprising porphyromonas gingivalis proteins and/or peptides and methods
AUPN901296A0 (en) 1996-03-29 1996-04-26 University Of Melbourne, The Porphyromonas gingivalis antigens for the diagnosis and treatment of periodontitis
US7341727B1 (en) 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
AUPP083997A0 (en) 1997-12-10 1998-01-08 Csl Limited Porphyromonas gingivalis nucleotides
US8129500B2 (en) 1997-12-10 2012-03-06 Csl Limited Porphyromonas gingivalis polypeptides and nucleotides
US6444799B1 (en) 1997-12-31 2002-09-03 Csl Limited P. gingivalis polynucleotides and uses thereof
US6627193B1 (en) 1999-01-13 2003-09-30 University Of Georgia Research Foundation, Inc. Methods and compositions for control of blood coagulation
AUPP893999A0 (en) 1999-03-01 1999-03-25 Csl Limited Synthetic peptides containing protective epitopes for the treatment and prevention of periodontitis associated with porphyromonas gingivalis
CA2373447A1 (en) 1999-05-12 2000-11-16 The General Hospital Corporation Permeabilizing biofilms
GB9913437D0 (en) 1999-06-09 1999-08-11 Medical Res Council Fusion proteins
AUPQ485999A0 (en) * 1999-12-24 2000-02-03 Csl Limited P. gingivalis antigenic composition
US20020009436A1 (en) * 1999-12-30 2002-01-24 Doyle Ron J. Methods and compositions for inhibiting adhesion by microorganisms
AUPQ718200A0 (en) 2000-04-28 2000-05-25 Csl Limited Porphyromonas gingivalis recombinant proteins and truncations
US6726898B2 (en) 2000-11-17 2004-04-27 Gary R. Jernberg Local delivery of agents for disruption and inhibition of bacterial biofilm for treatment of periodontal disease
US20030083287A1 (en) 2000-11-30 2003-05-01 Burgess Nicola A. ginS
AUPR575401A0 (en) 2001-06-18 2001-07-12 Unisearch Limited Method of causing sloughing
JP2003192616A (ja) 2001-12-27 2003-07-09 Univ Nihon 歯周病用ｄｎａワクチン
JP2003286191A (ja) 2002-03-27 2003-10-07 Univ Nihon 歯周病用粘膜免疫ワクチン
US20070036734A1 (en) 2003-03-17 2007-02-15 Kirin Beer Kabushiki Kaisha Therapeutic agent for periodontal disease
ZA200605660B (en) * 2003-12-19 2007-11-28 Univ Melbourne Antimicrobial composition
EP1721283B1 (en) 2004-02-06 2022-11-30 Council of Scientific and Industrial Research Computational method for identifying adhesin and adhesin-like proteins of therapeutic potential
US20070098649A1 (en) 2004-03-22 2007-05-03 The Board Of Trustees Of The University Of Illinois Method and composition for controlling oral pathogens
GB0411150D0 (en) 2004-05-19 2004-06-23 Queen Mary & Westfield College Vaccine
NZ554331A (en) 2004-09-23 2009-04-30 Univ Melbourne Antigenic complex for the diagnosis and treatment of porphyromonas gingivalis infection
US20060121031A1 (en) * 2004-12-07 2006-06-08 Mckenzie Brent S Relay vaccine
EP1888014B1 (en) * 2005-06-07 2012-11-14 The University of Melbourne Dental mineralization
WO2008016385A2 (en) 2006-01-20 2008-02-07 The University Of Washington Deacylase polypeptides, deacylase polynucleotides, and methods of use thereof
JP2009544279A (ja) * 2006-06-27 2009-12-17 オーラル ヘルス オーストラリア ピーティーワイ リミテッド 歯周病の予防に有用なポルフィロモナス・ジンジバリスポリペプチド
TWI369402B (en) * 2006-07-05 2012-08-01 Catalyst Biosciences Inc Protease screening methods and proteases identified thereby
WO2008124646A2 (en) 2007-04-06 2008-10-16 The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services Use of amyloid proteins as vaccine scaffolds
ES2432690T3 (es) * 2007-07-12 2013-12-04 Oral Health Australia Pty Ltd Tratamiento de biopelícula
CN101842486A (zh) 2007-07-12 2010-09-22 口腔健康澳洲私人有限公司 生物膜的免疫治疗
WO2010022463A1 (en) * 2008-08-29 2010-03-04 Oral Health Australia Pty Ltd Prevention, treatment and diagnosis of p.gingivalis infection
US9366673B2 (en) * 2009-08-02 2016-06-14 Sanofi Pasteur Limited Porphyromonas gingivalis polypeptides
KR101512053B1 (ko) 2009-09-03 2015-04-28 화이자 백신스 엘엘씨 Ｐｃｓｋ９ 백신
MX2012009926A (es) * 2010-02-25 2012-10-05 Vereniging Voor Christelijk Hoger Onderwijs Wetenschappelijk Onderzoek En Patientenzorg Un proceso para la preparacion de peptidos prolil sustituidos y peptidomimeticos similares.
MY162557A (en) 2010-02-26 2017-06-15 Oral Health Australia Pty Ltd Treatment or prevention of infection
TWI542695B (zh) * 2010-12-15 2016-07-21 日星股份有限公司 牙周病原菌血漿或血清抗體價檢查套組
DE102011003604A1 (de) 2011-02-03 2012-08-09 Battenfeld-Cincinnati Germany Gmbh Kühlvorrichtung und Kühlverfahren
JP6310631B2 (ja) 2011-10-18 2018-04-11 サンスター株式会社 歯周病原菌血漿または血清抗体価検査キット
WO2016191389A2 (en) * 2015-05-27 2016-12-01 Merial, Inc. Compositions containing antimicrobial igy antibodies, for treatment and prevention of disorders and diseases caused by oral health compromising (ohc) microorganisms
CN108369232B (zh) 2015-12-09 2022-05-31 豪夫迈·罗氏有限公司 人IgG1结合多聚抗原的直接亲和力测量
JP6788010B2 (ja) 2015-12-09 2020-11-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ インビボ相互作用様式を決定するための方法
CN108038398B (zh) * 2017-12-22 2021-03-23 珠海市君天电子科技有限公司 一种二维码解析能力测试方法、装置及电子设备

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040005276A1 (en) * 1997-04-30 2004-01-08 Reynolds Eric Charles Synthetic peptide constructs for the diagnosis and treatment of periodontitis associated with porphyromonas gingivalis
WO2005019249A2 (en) * 2003-08-15 2005-03-03 University Of Florida Identification of porphyromonas gingivalis virulence polynucleotides for diagnosis, treatment, and monitoring of periodontal diseases

Also Published As

Publication number Publication date
US20110280880A1 (en) 2011-11-17
US9518109B2 (en) 2016-12-13
RU2535898C2 (ru) 2014-12-20
DK2328914T3 (en) 2017-07-10
US11572391B2 (en) 2023-02-07
US20170247420A1 (en) 2017-08-31
CA2735171A1 (en) 2010-03-04
KR101721904B1 (ko) 2017-04-11
WO2010022463A1 (en) 2010-03-04
RU2011108943A (ru) 2012-10-10
JP2015212284A (ja) 2015-11-26
EP2328914A1 (en) 2011-06-08
JP6235533B2 (ja) 2017-11-22
US20150079095A1 (en) 2015-03-19
BRPI0917321A2 (pt) 2015-11-17
ZA201101814B (en) 2016-10-26
CN107266582A (zh) 2017-10-20
MX2011001949A (es) 2011-07-20
MY178905A (en) 2020-10-22
KR20110061586A (ko) 2011-06-09
NZ598834A (en) 2013-06-28
US20210079047A1 (en) 2021-03-18
EP3255057A1 (en) 2017-12-13
CN102203121A (zh) 2011-09-28
TWI473626B (zh) 2015-02-21
TW201021845A (en) 2010-06-16
US8871213B2 (en) 2014-10-28
AU2009287340A1 (en) 2010-03-04
US20190194263A1 (en) 2019-06-27
EP2328914B1 (en) 2017-05-10
JP2012500633A (ja) 2012-01-12
EP3255057B1 (en) 2020-03-18
CA2735171C (en) 2023-10-03
US20230374081A1 (en) 2023-11-23
CN107266582B (zh) 2021-09-10
EP2328914A4 (en) 2012-12-19
PL2328914T3 (pl) 2017-09-29
US10851138B2 (en) 2020-12-01
NZ591612A (en) 2012-08-31
ES2633738T3 (es) 2017-09-25
IL211394B (en) 2018-07-31

Similar Documents

Publication Publication Date Title
US11572391B2 (en) Antibodies for prevention, treatment and diagnosis of P. gingivalis infection
JP5349448B2 (ja) Ｐ．ｇｉｎｇｉｖａｌｉｓ抗原組成物
HK1248535A1 (en) Treatment or prevention of infection
AU2013203249A1 (en) Prevention, treatment and diagnosis of P.gingivalis infection
HK1157357B (en) Prevention, treatment and diagnosis of p.gingivalis infection
HK1157357A (en) Prevention, treatment and diagnosis of p.gingivalis infection

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)